Molecular and Cellular Oncology Program

分子和细胞肿瘤学项目

• 批准号: 10332912
• 负责人: RICHARD D SCHULICK
• 金额: $ 5.62万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-04 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10332912
• 关键词: Adult; Aging; Aneuploidy; Animal Model; Automobile Driving; Autophagocytosis; BCL2 gene; BRAF gene; Basic Science; Bioinformatics; Biological Sciences; Biometry; Biotechnology; CRISPR screen; Cancer Center; Cancer Center Support Grant; Cancer Patient; Catchment Area; Cells; Cellular biology; Chloroquine; Chromatin Remodeling Factor; Clinical; Clinical Research; Clinical Trials; Collaborations; Colorado; Combined Modality Therapy; Communities; Community Outreach; Copy Number Polymorphism; Custom; DNA Damage; DNA Repair; DNA amplification; Databases; Dependence; Development; Diagnosis; Disease; Disease remission; Down Syndrome; Drug resistance; Epigenetic Process; Equilibrium; Flow Cytometry; Fostering; Funding; Future; Gene Expression; Genes; Genetic Models; Genetic Screening; Genetic Transcription; Genetic study; Genomic Instability; Genomics; Goals; Grant; Guide RNA; Head and neck structure; Health; Hematologic Neoplasms; Histone Deacetylase Inhibitor; Individual; Institutes; Institution; Investigation; Jordan; Journals; Knowledge; Leadership; Lung; MAP Kinase Gene; MAPK Signaling Pathway Pathway; MDM2 gene; Malignant Neoplasms; Malignant neoplasm of brain; Mediator of activation protein; Medical; Medicine; Mentors; Metabolic; Metabolism; Mission; Molecular; Molecular Structure; Mutation; Nature; Pathology; Patients; Peer Review; Predisposition; Process; Proteins; Publications; Publishing; RNA; RNA Processing; RNA library; Radiation-Sensitizing Agents; Research; Research Peer Review; Research Personnel; Resistance; Resource Sharing; Resources; Science; Seeds; Signal Transduction; Site; TP53 gene; Technology; Telomerase; Telomere Pathway; Testing; The University of Colorado Cancer Center; Therapeutic; Time; Training; Training Programs; Translating; Translational Research; Translations; Underserved Population; Universities; Woman; anticancer research; bench to bedside; cancer cell; cancer diagnosis; cancer genome; cancer prevention; cancer therapy; career development; cellular oncology; chemotherapy; community engagement; design; epigenetic regulation; experience; experimental study; follower of religion Jewish; functional genomics; fundamental research; genome integrity; improved; inhibitor; insight; interdisciplinary collaboration; kinase inhibitor; leukemic stem cell; malignant breast neoplasm; member; molecular oncology; new combination therapies; new technology; novel; novel diagnostics; novel therapeutic intervention; novel therapeutics; oncology program; personalized medicine; pre-clinical; prognostic value; programs; promoter; response; structural biology; telomere; tumor metabolism; tumor progression

ABSTRACT Overview and Goals: The goal of the Molecular and Cellular Oncology (MCO) program is to perform in-depth mechanistic studies in pursuit of critical basic science knowledge that can be applied towards effective cancer prevention, diagnosis, and treatment. The expertise of program members is broad and deep, with major strengths in genome instability, gene expression and epigenetic regulation, DNA damage responses, telomeres, pathways controlling cell fate, and elucidation of cancer-relevant molecular structures. Research Highlights: Bench-to- bedside team science uncovered metabolic vulnerabilities of leukemia stem cells and contributed to a new therapy combination of BCL-2 inhibitor Venetoclax with standard chemotherapy that produces deep and durable remissions (Cancer Cell, 2018 [1,2]; Nature Medicine, 2018 [3]) and the finding that adding autophagy inhibitor chloroquine to BRAF inhibitor vemurafenib reduced inhibitor resistance for brain cancer patients (Elife, 2017 [4]; PNAS, 2018 [5]). Program Activities: To accomplish its goals, MCO co-leaders employ resources provided by the University of Colorado Cancer Center (UCCC) to encourage and enable intra- and inter-programmatic collaborations through organization of annual retreats and technology forums as well as fostering transdisciplinary collaborations. Assisted by UCCC support, the co-leaders catalyze new research by MCO members through the creation and expansion of Shared Resources (SR), by providing pilot funding to use these technologies, while leveraging resources and research strengths of collaborating institutions. Through coordinated transdisciplinary collaborations between MCO members and translational/clinical research programs, the discoveries made in MCO move from bench to preclinical investigations and clinical trials, which ultimately improve diagnosis, treatment, and prevention of cancer. Members: The program has 56 full and 13 mentored members with $ 4.7M NCI and $9.0M of other cancer peer-reviewed research funding. Members are from 13 basic science and clinical departments at UCAMC, UCB, CSU and National Jewish Health (NJH). Since July 2016, MCO members published 476 cancer-focused publications, of which 245 (51%) were either inter-programmatic (45%), intra- programmatic (17%), or both (11%); (27%) were in journals with an IF ≥10; and 130 (27%) represented collaborations with investigators at other NCI cancer centers. Future Directions: Through retreats/forums, seed grants, and support of relevant SRs, MCO plans to enhance current strengths in the cross-cutting research themes cancer and metabolism and cancer and aging. To promote collaborative translational research of relevance to the catchment, MCO members are collaborating with the UCCC Office of Community Outreach and Engagement to mine patient databases from the Colorado Center for Personalized Medicine for cancer-relevant genomic information in underserved populations in Colorado. Findings will be shared with MCO members to stimulate catchment-relevant cancer research. These efforts will advance the discovery of basic cancer processes and their translation into improved cancer prevention and treatment.

摘要 概述和目标：分子和细胞肿瘤学（MCO）计划的目标是进行深入的 机制研究，追求关键的基础科学知识，可以应用于有效的癌症 预防、诊断和治疗。计划成员的专业知识广泛而深入，具有主要优势 在基因组不稳定性，基因表达和表观遗传调控，DNA损伤反应，端粒，途径 控制细胞命运和阐明癌症相关分子结构。研究亮点：从实验室到 床边团队科学发现了白血病干细胞的代谢脆弱性，并促成了一个新的 BCL-2抑制剂维奈托克与标准化疗的联合治疗， 缓解（Cancer Cell，2018 [1，2]; Nature Medicine，2018 [3]）以及添加自噬抑制剂 氯喹对BRAF抑制剂维罗非尼降低了脑癌患者的抑制剂耐药性（Elife，2017 [4]; PNAS，2018 [5]）。计划活动：为了实现其目标，MCO共同领导人利用由以下机构提供的资源： 科罗拉多大学癌症中心（UCCC）鼓励和支持项目内和项目间的 通过组织年度务虚会和技术论坛以及促进跨学科合作， 合作。在UCCC的支持下，联合领导人通过 创建和扩大共享资源（SR），为使用这些技术提供试点资金， 利用合作机构的资源和研究优势。通过协调的跨学科 MCO成员与转化/临床研究项目之间的合作， MCO从实验室转向临床前研究和临床试验，最终改善诊断， 治疗和预防癌症。成员：该计划有56名正式成员和13名指导成员，价值470万美元 NCI和900万美元的其他癌症同行评审研究资金。成员来自13个基础科学和临床 UCAMC，UCB，CSU和国家犹太健康（NJH）的部门。自2016年7月以来，MCO成员 发表了476篇以癌症为重点的出版物，其中245篇（51%）是跨计划（45%）、内部（45%）、 程序性（17%），或两者兼而有之（11%）;（27%）在IF ≥10的期刊中; 130（27%）代表 与其他NCI癌症中心的研究人员合作。未来方向：通过务虚会/论坛，种子 赠款和相关工作人员代表的支持，MCO计划加强跨领域研究的现有优势 主题是癌症和新陈代谢以及癌症和衰老。促进合作翻译研究， 与集水区相关，MCO成员正在与UCCC社区外展办公室合作， 参与挖掘来自科罗拉多个性化医学中心的患者数据库， 基因组信息在科罗拉多缺乏服务的人群。调查结果将与MCO成员分享， 促进与流域有关的癌症研究。这些努力将推进基础癌症的发现 过程及其转化为改进的癌症预防和治疗。